Case number 2018-1054
Endo Pharmaceuticals Inc. v. Actavis LLC > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | ENDO PHARMACEUTICALS INC. v. ACTAVIS LLC [OPINION - PRECEDENTIAL] [precedential] (0) |
| Jun 10, 2019 | 72 | Mandate issued to the United States District Court for the District of Delaware. Service as of this date by the Clerk of Court. [612687] [JAB] [Entered: 06/10/2019 10:20 AM] (1) |
| May 3, 2019 | 71 | JUDGMENT filed. AFFIRMED. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [604835] [PBC] [Entered: 05/03/2019 10:29 AM] (2) |
| May 3, 2019 | 70 | OPINION filed for the court by Wallach, Circuit Judge; Clevenger, Circuit Judge and Stoll, Circuit Judge. Dissenting opinion filed by Circuit Judge Stoll. Precedential Opinion. [604833] [PBC] [Entered: 05/03/2019 10:28 AM] (31) |
| Dec 6, 2018 | 69 | Submitted after ORAL ARGUMENT by Mr. John C. O'Quinn for Teva Pharmaceuticals USA, Inc., Actavis LLC and Actavis South Atlantic LLC and Mr. Martin Jay Black, Esq. for Endo Pharmaceuticals Inc. and Mallinckrodt LLC. Panel: Judge: Wallach , Judge: Clevenger , Judge: Stoll. [569863] [JCP] [Entered: 12/06/2018 11:20 AM] (0) |
| Dec 3, 2018 | 68 | AMENDED NOTICE OF ORAL ARGUMENT. Panel: 1812M. Case scheduled Dec 06, 2018 9:30 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 203. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [569429] [JCP] [Entered: 12/03/2018 05:01 PM] (2) |
| Nov 16, 2018 | 67 | Response to oral argument order from the Appellee Mallinckrodt LLC.[565854] [18-1054] [Jeffrey Toney] [Entered: 11/16/2018 02:18 PM] (3) |
| Nov 16, 2018 | 66 | Notice to counsel for Appellee Mallinckrodt LLC: The record of this case indicates that the Response to Notice of Oral Argument has not been filed. The response was due on or before 11/15/2018. Counsel must promptly docket the Response to Notice of Oral Argument event and designate which attorney will present argument for the party. Service as of this date by the Clerk of Court. [565680] [JAB] [Entered: 11/16/2018 08:51 AM] (0) |
| Nov 15, 2018 | 65 | Response to oral argument order from the Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc..[565478] [18-1054] [William Burgess] [Entered: 11/15/2018 04:03 PM] (3) |
| Nov 15, 2018 | 64 | Response to oral argument order from the Appellee Endo Pharmaceuticals Inc..[565435] [18-1054] [Martin Black] [Entered: 11/15/2018 03:39 PM] (3) |
| Oct 22, 2018 | 63 | NOTICE OF ORAL ARGUMENT. Panel: 1812M. Case scheduled Dec 06, 2018 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 203. Response to Notice of Oral Argument due: 11/15/2018. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [559169] [JAB] [Entered: 10/22/2018 01:54 PM] (2) |
| Oct 11, 2018 | 62 | Notice from Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument (request not to schedule oral argument during the same week as No. 17-2354, 18-1053, 18-1376, or 18-1397). Service: 10/11/2018 by email. [556535] [18-1054] [John O'Quinn] [Entered: 10/11/2018 09:52 PM] (2) |
| Oct 2, 2018 | 61 | Notice from Appellee Endo Pharmaceuticals Inc. regarding conflicts with oral argument (February 4-8, 2019 and not be scheduled for argument in the same week as the argument for Intellectual Ventures I, LLC et al. v. T-Mobile USA, Inc. et al., Appeal Nos. 17-2601, 17-2604, 17-2608, 17-2610, 18-1027, 18-1029, 18-1033.). Service: 10/02/2018 by email. [554262] [18-1054] [Martin Black] [Entered: 10/02/2018 04:12 PM] (2) |
| Aug 8, 2018 | 60 | Notice from Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument ([update from 6/15/2018 letter]: request not to schedule oral argument October 4 or 5, or during the same week as nos. 17-2247, 17-2354, or 17-2348.). Service: 08/08/2018 by email. [541545] [18-1054] [John O'Quinn] [Entered: 08/08/2018 02:18 PM] (3) |
| Jul 2, 2018 | 59 | Notice from Appellee Endo Pharmaceuticals Inc. regarding conflicts with oral argument (September 4-6, 2018). Service: 07/02/2018 by email. [533155] [18-1054] [Martin Black] [Entered: 07/02/2018 02:53 PM] (3) |
| Jun 25, 2018 | 58 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks [SEP, OCT, NOV], or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 07/02/2018. [531705] [MJL] [Entered: 06/25/2018 01:49 PM] (0) |
| Jun 20, 2018 | 57 | 6 paper copies of the Corrected Confidential Joint Appendix Brief (Volume I-II) [55] received from Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. [530818] [CJF] [Entered: 06/20/2018 10:43 AM] (0) |
| Jun 15, 2018 | 56 | Notice from Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument (request not to schedule oral argument during the same week as no. 17-2490, 17-2247, 17-2354, or 17-2348). Service: 06/15/2018 by email. [529938] [18-1054] [John O'Quinn] [Entered: 06/15/2018 02:54 PM] (2) |
| Jun 11, 2018 | 55 | CORRECTED APPENDIX FILED for Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. [52]. Number of Pages: 1207. Service: 06/11/2018 by email. Paper copies should be provided of the confidential version only. [529436] [MJL] [Entered: 06/14/2018 01:59 PM] (1207) |
| Jun 11, 2018 | 54 | CORRECTED CONFIDENTIAL JOINT APPENDIX FILED for Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. [53]. Number of Pages: 1261. Service: 06/11/2018 by US mail, email. The paper copies of the confidential version of the appendix should be received by the court on or before 06/21/2018. [529434] [MJL] [Entered: 06/14/2018 01:56 PM] (0) |
| Jun 11, 2018 | 53 | TENDERED from Appellants Actavis LLC, Actavis South Atlantic LLC, Teva Pharmaceuticals USA, Inc. and Appellees Endo Pharmaceuticals Inc. and Mallinckrodt LLC. Title: CORRECTED CONFIDENTIAL JOINT APPENDIX Service: 06/11/2018 by email. [528559] [18-1054] [William Burgess] [Entered: 06/11/2018 07:10 PM] (0) |
| Jun 11, 2018 | 52 | TENDERED from Appellants Actavis LLC, Actavis South Atlantic LLC, Teva Pharmaceuticals USA, Inc. and Appellees Endo Pharmaceuticals Inc. and Mallinckrodt LLC. Title: CORRECTED JOINT APPENDIX. Service: 06/11/2018 by email. [528558] [18-1054] [William Burgess] [Entered: 06/11/2018 07:05 PM] (1207) |
| Jun 1, 2018 | 51 | NOTICE OF REJECTION: The Joint Appendix (nonconfidential [47], confidential [48]) is not in compliance with the rules of this court and is therefore rejected for filing. Corrected appendix due 06/15/2018. Service as of this date by the Clerk of Court. [526071]--[Edited 06/01/2018 by MJL to correct typographical error]. [MJL] [Entered: 06/01/2018 08:47 AM] (2) |
| May 31, 2018 | 50 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Actavis LLC, Actavis South Atlantic LLC, Teva Pharmaceuticals USA, Inc. and Appellees Endo Pharmaceuticals Inc. and Mallinckrodt LLC. Service: 05/31/2018 by email. [525975] [18-1054] [William Burgess] [Entered: 05/31/2018 04:10 PM] (3) |
| May 31, 2018 | 49 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellants Actavis LLC, Actavis South Atlantic LLC, Teva Pharmaceuticals USA, Inc. and Appellees Endo Pharmaceuticals Inc. and Mallinckrodt LLC. Service: 05/31/2018 by email. [525973] [18-1054] [William Burgess] [Entered: 05/31/2018 04:09 PM] (3) |
| May 30, 2018 | 48 | TENDERED from Appellants Actavis LLC, Actavis South Atlantic LLC, Teva Pharmaceuticals USA, Inc. and Appellees Endo Pharmaceuticals Inc. and Mallinckrodt LLC. Title: CONFIDENTIAL JOINT APPENDIX Service: 05/30/2018 by email. [525666] [18-1054]. This appendix has been rejected. See Doc. No. [51]. [William Burgess] [Entered: 05/30/2018 10:17 PM] (0) |
| May 30, 2018 | 47 | TENDERED from Appellants Actavis LLC, Actavis South Atlantic LLC, Teva Pharmaceuticals USA, Inc. and Appellees Endo Pharmaceuticals Inc. and Mallinckrodt LLC. Title: JOINT APPENDIX. Service: 05/30/2018 by email. [525665] [18-1054]. This appendix has been rejected. See Doc. No. [51]. [William Burgess] [Entered: 05/30/2018 10:12 PM] (0) |
| May 29, 2018 | 45 | 6 paper copies of the Corrected Opening Response Brief [43] received from Appellees Endo Pharmaceuticals Inc. and Mallinckrodt LLC. [524957] [CJF] [Entered: 05/29/2018 11:09 AM] (0) |
| May 25, 2018 | 46 | 6 paper copies of the Reply Brief [44] received from Appellants Actavis LLC and Actavis South Atlantic LLC. [525306] [SJL] [Entered: 05/30/2018 10:20 AM] (0) |
| May 24, 2018 | 43 | CORRECTED BRIEF FILED for Appellees Endo Pharmaceuticals Inc. and Mallinckrodt LLC [42]. Number of Pages: 72. Service: 05/24/2018 by email. The paper copies of the brief should be received by the court on or before 06/01/2018. [524443] [MJL] [Entered: 05/24/2018 03:28 PM] (90) |
| May 24, 2018 | 42 | TENDERED from Appellees Endo Pharmaceuticals Inc. and Mallinckrodt LLC. Title: CORRECTED RESPONSE BRIEF. Service: 05/24/2018 by email. [524427] [18-1054] [Martin Black] [Entered: 05/24/2018 03:14 PM] (90) |
| May 23, 2018 | 44 | REPLY BRIEF FILED for Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. [41]. Number of Pages: 38. Service: 05/23/2018 by email. The paper copies of the brief should be received by the court on or before 06/01/2018. Appendix is due 05/30/2018. [524460] [MJL] [Entered: 05/24/2018 03:41 PM] (45) |
| May 23, 2018 | 41 | TENDERED from Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Title: REPLY BRIEF. Service: 05/23/2018 by email. [524095] [18-1054] [William Burgess] [Entered: 05/23/2018 09:07 PM] (45) |
| May 18, 2018 | 40 | ORDER filed. The motion [35] is denied without prejudice to Endo filing a corrected brief or a new motion with a corrected brief to the extent provided herein within 10 days of the date of filing of this order. Service: 05/18/2018 by clerk. [522879] [NL] [Entered: 05/18/2018 01:10 PM] (3) |
| Apr 13, 2018 | 39 | ORDER filed. The motion [38] is granted. The appellants' reply brief is due May 23, 2018. Service: 04/13/2018 by clerk. [513164] [LMS] [Entered: 04/13/2018 10:23 AM] (2) |
| Apr 12, 2018 | 38 | MOTION of Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. to extend the time to 05/23/2018 to file the Reply Brief.. Any response is due within 10 days of service. [Consent: unopposed]. Service: 04/12/2018 by email. [512695] [18-1054] [William Burgess] [Entered: 04/12/2018 12:19 AM] (7) |
| Apr 9, 2018 | 37 | TENDERED from Appellees Endo Pharmaceuticals Inc. and Mallinckrodt LLC. Title: CONFIDENTIAL RESPONSE BRIEF Service: 04/09/2018 by email. [511857] [18-1054]. This brief has been corrected. See Doc. No. [43]. [Martin Black] [Entered: 04/09/2018 05:57 PM] (0) |
| Apr 9, 2018 | 36 | TENDERED from Appellees Endo Pharmaceuticals Inc. and Mallinckrodt LLC. Title: RESPONSE BRIEF. Service: 04/09/2018 by email. [511856] [18-1054]. This brief has been corrected. See Doc. No. [43]. [Martin Black] [Entered: 04/09/2018 05:56 PM] (0) |
| Apr 9, 2018 | 35 | MOTION of Appellees Endo Pharmaceuticals Inc. and Mallinckrodt LLC to waive confidentiality requirements. Any response is due within 10 days of service. [Consent: unopposed]. Service: 04/09/2018 by email. [511854] [18-1054] [Martin Black] [Entered: 04/09/2018 05:55 PM] (11) |
| Apr 9, 2018 | 34 | Entry of appearance for Robert D. Rhoad as of counsel for Appellee Endo Pharmaceuticals Inc.. Service: 04/09/2018 by email. [511852] [18-1054] [Martin Black] [Entered: 04/09/2018 05:53 PM] (2) |
| Mar 22, 2018 | 33 | **TEXT ONLY** ORDER granting motion to extend time to file appellees' response brief [32] filed by Appellees Endo Pharmaceuticals Inc. and Mallinckrodt LLC. The brief is due 04/09/2018. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [507042] [MJL] [Entered: 03/22/2018 09:33 AM] (0) |
| Mar 22, 2018 | 32 | MOTION of Appellees Endo Pharmaceuticals Inc. and Mallinckrodt LLC to extend the time to 04/09/2018 to file the Response Brief.. Any response is due within 10 days of service. [Consent: unopposed]. Service: 03/22/2018 by email. [507025] [18-1054] [Blake Greene] [Entered: 03/22/2018 09:21 AM] (11) |
| Mar 16, 2018 | 31 | Note to file: 18-1054 (COMPANION started 03/16/2018) with 17-1240, -1455, -1887. These cases shall be considered companion cases and assigned to the same merits panel for oral argument. [505900] [17-1240, 18-1054] [MJL] [Entered: 03/16/2018 11:29 AM] (0) |
| Feb 21, 2018 | 30 | 6 paper copies of the Opening Brief [29] received from Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. [500132] [JCP] [Entered: 02/22/2018 07:52 AM] (0) |
| Feb 13, 2018 | 29 | BRIEF FILED for Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. [28]. Number of Pages: 75. Service: 02/13/2018 by email. The paper copies of the brief should be received by the court on or before 02/23/2018. Appellees' brief(s) due 03/26/2018. [497955] [MJL] [Entered: 02/15/2018 09:29 AM] (152) |
| Feb 13, 2018 | 28 | TENDERED from Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Title: OPENING BRIEF. Service: 02/13/2018 by email. [497493] [William Burgess] [Entered: 02/13/2018 07:34 PM] (152) |
| Feb 13, 2018 | 27 | Amended Certificate of Interest for the Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 02/13/2018 by email. [497492] [William Burgess] [Entered: 02/13/2018 07:32 PM] (3) |
| Dec 5, 2017 | 26 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: Appellant's motion [24] did not include a certificate of compliance. CORRECTION: Pursuant to FRAP 32(g)(1), motions must contain a certificate of compliance with the word count. Please ensure future motions include the certificate of compliance. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [480334] [MJL] [Entered: 12/05/2017 02:04 PM] (0) |
| Dec 5, 2017 | 25 | **TEXT ONLY** ORDER granting motion to extend time to file appellant's principal brief [24] filed by Appellants Teva Pharmaceuticals USA, Inc., Actavis LLC and Actavis South Atlantic LLC. The brief is due 02/13/2018. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [480333] [MJL] [Entered: 12/05/2017 02:03 PM] (0) |
| Dec 5, 2017 | 24 | MOTION of Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc. to extend the time to 02/13/2018 to file the appellant/petitioner's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 12/05/2017 by email. [480318] [William Burgess] [Entered: 12/05/2017 01:23 PM] (6) |
| Oct 31, 2017 | 23 | Corrected Certificate of Interest for the Appellee Mallinckrodt LLC. Service: 10/31/2017 by email. [471984] [Jeffrey Toney] [Entered: 10/31/2017 03:00 PM] (4) |
| Oct 31, 2017 | 22 | Corrected Entry of appearance for Eric H. Yecies as of counsel for Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 10/31/2017 by email. [471851] [William Burgess] [Entered: 10/31/2017 11:25 AM] (2) |
| Oct 31, 2017 | 21 | Corrected Entry of appearance for Charles A. Weiss as of counsel for Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 10/31/2017 by email. [471849] [William Burgess] [Entered: 10/31/2017 11:24 AM] (2) |
| Oct 31, 2017 | 20 | NOTICE OF DEFICIENCY: The certificate of interest [4] filed by Appellee Mallinckrodt LLC in 18-1054 is incomplete and therefore cannot be accepted for filing at this time. The filing did not include item #5 (see FCR 47.4(a)(5)). You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [471842] [MJL] [Entered: 10/31/2017 11:20 AM] (0) |
| Oct 31, 2017 | 19 | NOTICE OF DEFICIENCY: The entries of appearance for Charles A. Weiss [15] and Eric H. Yecies [16] filed by Appellants Teva Pharmaceuticals USA, Inc., Actavis LLC and Actavis South Atlantic LLC in 18-1054 indicate more than one principal attorney for the parties and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected documents may be accepted for filing if received before midnight (EST) on the date of this notice. [471838] [MJL] [Entered: 10/31/2017 11:15 AM] (0) |
| Oct 30, 2017 | 18 | Docketing Statement for the Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 10/30/2017 by email. [471704] [William Burgess] [Entered: 10/30/2017 11:39 PM] (3) |
| Oct 30, 2017 | 17 | Certificate of Interest. Service: by email. [471703] Certificate of Interest for the Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 10/30/2017 by email. [471703] [William Burgess] [Entered: 10/30/2017 11:38 PM] (3) |
| Oct 30, 2017 | 16 | Entry of appearance for Eric H. Yecies as of counsel for Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 10/30/2017 by email. [471702] [William Burgess] [Entered: 10/30/2017 11:38 PM] (0) |
| Oct 30, 2017 | 15 | Entry of appearance for Charles A. Weiss as of counsel for Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 10/30/2017 by email. [471701] [William Burgess] [Entered: 10/30/2017 11:37 PM] (0) |
| Oct 30, 2017 | 14 | Entry of appearance for William H. Burgess as of counsel for Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 10/30/2017 by email. [471700] [William Burgess] [Entered: 10/30/2017 11:36 PM] (2) |
| Oct 30, 2017 | 13 | Entry of appearance for John C. O'Quinn as principal counsel for Appellants Actavis LLC, Actavis South Atlantic LLC and Teva Pharmaceuticals USA, Inc.. Service: 10/30/2017 by email. [471699] [William Burgess] [Entered: 10/30/2017 11:35 PM] (2) |
| Oct 30, 2017 | 12 | Docketing Statement for the Appellee Endo Pharmaceuticals Inc.. Service: 10/30/2017 by email. [471689] [Martin Black] [Entered: 10/30/2017 08:52 PM] (4) |
| Oct 30, 2017 | 11 | Certificate of Interest for the Appellee Endo Pharmaceuticals Inc.. Service: 10/30/2017 by email. [471687] [Martin Black] [Entered: 10/30/2017 08:50 PM] (4) |
| Oct 30, 2017 | 10 | Entry of appearance for Jonathan D.J. Loeb as of counsel for Appellee Endo Pharmaceuticals Inc.. Service: 10/30/2017 by email. [471686] [Martin Black] [Entered: 10/30/2017 08:48 PM] (2) |
| Oct 30, 2017 | 9 | Entry of appearance for Blake B. Greene as of counsel for Appellee Endo Pharmaceuticals Inc.. Service: 10/30/2017 by email. [471685] [Martin Black] [Entered: 10/30/2017 08:45 PM] (2) |
| Oct 30, 2017 | 8 | Entry of appearance for Sharon K. Gagliardi as of counsel for Appellee Endo Pharmaceuticals Inc.. Service: 10/30/2017 by email. [471684] [Martin Black] [Entered: 10/30/2017 08:43 PM] (2) |
| Oct 30, 2017 | 7 | Entry of appearance for Martin J. Black as principal counsel for Appellee Endo Pharmaceuticals Inc.. Service: 10/30/2017 by email. [471683] [Martin Black] [Entered: 10/30/2017 08:41 PM] (2) |
| Oct 30, 2017 | 6 | Entry of appearance for Paul G. Williams as of counsel for Appellee Mallinckrodt LLC. Service: 10/30/2017 by email. [471539] [Paul Williams] [Entered: 10/30/2017 04:30 PM] (2) |
| Oct 30, 2017 | 5 | Entry of appearance for Rodney R. Miller as of counsel for Appellee Mallinckrodt LLC. Service: 10/30/2017 by email. [471536] [Rodney Miller] [Entered: 10/30/2017 04:27 PM] (2) |
| Oct 30, 2017 | 4 | Certificate of Interest for the Appellee Mallinckrodt LLC. Service: 10/30/2017 by email. [471531] [Jeffrey Toney] [Entered: 10/30/2017 04:23 PM] (0) |
| Oct 30, 2017 | 3 | Docketing Statement for the Appellee Mallinckrodt LLC. Service: 10/30/2017 by email. [471526] [Jeffrey Toney] [Entered: 10/30/2017 04:22 PM] (4) |
| Oct 30, 2017 | 2 | Entry of appearance for Jeffrey J. Toney as principal counsel for Appellee Mallinckrodt LLC. Service: 10/30/2017 by email. [471524] [Jeffrey Toney] [Entered: 10/30/2017 04:21 PM] (2) |
| Oct 16, 2017 | 1 | Appeal docketed. Received: 10/16/2017. [467909]Entry of Appearance due 10/30/2017. Certificate of Interest due 10/30/2017. Docketing Statement due 10/30/2017. Appellants' brief due 12/15/2017. [MJL] [Entered: 10/16/2017 11:05 AM] (65) |
